2 June 06:41
An experimental pill from AstraZeneca has shown a 56% reduction in the risk of breast cancer progression, according to a study presented at ASCO
Adrian Rusu
Health
Foto: pixabay.com/ro
Administration of AstraZeneca's experimental pill camizestrant to breast cancer patients at the first sign of resistance to standard therapies cut the risk of disease progression or death in half, according to results presented Sunday at the American Society of Clinical Oncology (ASCO) meeting in Chicago.
Dr. Eleonora Teplinsky, an oncologist at Valley-Mount Sinai Comprehensive Cancer Care, said this early approach reduced the risk of disease progression or death by 56%.
Sources
Studiu: O pastilă experimentală reduce cu peste 50% riscul de progresie a cancerului de sân
Veste-bombă de la AstraZeneca: dezvăluiri despre pastila ce va reduce la jumătate riscul de progresie a cancerului de sân
Un tratament al AstraZeneca cu o pastilă, bazat pe un test de sânge, reduce la jumătate riscul de progresie a cancerului de sân
Personalized news feed, AI-powered search, and notifications in a more interactive experience.
